95 research outputs found
Emotional Intelligence in the Educational and Therapeutic Community in Nepal
Emotional intelligence has been gaining increased attention in both the educational as well as therapeutic communities of Nepal. Research suggests that development of emotional intelligence has a significant influence on an individual’s achievements including academic success and is seen as a key aspect of positive development (Mayer, Salovey, & Caruso, 2004). Ankur Counseling Center in Kathmandu was established in 2006, primarily to work with children who have experienced great stress in their lives. Counselors at Ankur have been using play and sand tray therapy to understand the emotional lives of their clients, as well as to assist the process of emotional healing.
DOI: http://dx.doi.org/10.3126/jer.v2i0.7621
Journal of Education and Research Vol. 2, 2010 p.35-4
The Ursinus Weekly, January 14, 1957
McClure releases statement on new funds for UC • UC evaluation to be held in Feb. • Committee begins work on Campus Chest plans • Y to hear speaker Wed. • WSGA plans forum on student government • Frosh to present Show boat on January 18 • Canterbury Club hears Busler, plans Communion • Two brothers of APE announce engagements • Two Deltas engaged New Year\u27s to Ursinus women • Symons accepts state post in administrative dept. • Twelve Ursinus seniors to be included in 1957 Who\u27s who • Washington trip planned by WRC • MSGA council discusses plans for second semester • Chi Alpha to hear views on evangelism tonight • KDK drive yields 300 lbs. of clothing for Hungary • Two Sig Rho-ers pinned • Reese - Ruth engagement • Noted showman to talk at Feb. Forum • Editorial: Some comments on culture • Da Nighta afta Chrismist • Letters to the editor • Love conquereth all • American theatre: Sophistication or drama • Drexel, Delaware hand J.V. cagers first two defeats • Badminton belles begin practice • Bailey gains new post in E.C.A.C. • Heavyweight forfeit gives Fords 18-18 tie with Bruin matmen Sat. • Losing streak goes to 7 as cagers lose to Drexel, Hens • Finals schedule to be published January 21 • Herman - Eggenhofer engagement • Shelly - Frank engagementhttps://digitalcommons.ursinus.edu/weekly/1419/thumbnail.jp
The Ursinus Weekly, February 25, 1957
SGAs to sponsor forum on governments on Monday, Mar. 4 • Freshman women receive colors at program, Thurs. • Seniors to give original musical comedy, April 5, 6 • Lisle field representative to visit Ursinus tomorrow • Scholarship fund set up at U.C. by railroad company • Delta Pi man returns • Weekly to conduct vote on Wed. for best-dressed girl • UC Debating Club meets Lehigh and Rutgers of N.J. • Four charities to be supported in Campus Chest drive, March 4 to 15 • Sonnie Smith, Marge Struth voted May Queen, manager • Men\u27s government meets at advisor\u27s home • Curtain Club to present Valiant • WAA, Varsity Club hold annual dance, Friday • Curtain Club group plays for April announced • Future activities planned by U.C. Canterbury Club • Curtain Club announces name of Spring play • No classes Good Friday • Editorial: Memoranda for March 4 • Cynic • Report on the Perkiomen • Star-reaching • Who is the best-dressed woman at Ursinus? • Bears lose to Del., Rutgers; Meet division champs Wed. • U.C. to send Padula, Prutzman and Knauf to championships at G\u27burg • Prutzman stays undefeated as matmen topple cadets • Mermaids sink to Swarthmore, Wed. • Belles top G-burg; Drop first loss to Beaverhttps://digitalcommons.ursinus.edu/weekly/1422/thumbnail.jp
The Ursinus Weekly, February 18, 1957
Visiting group to complete U.C. evaluation this week • Twenty students enter at mid-year • Men\u27s council hears suggestions • Curtain Club to present The Valiant on Feb. 26 • W.F. Speilman, member of UC maintenance staff, dies • Chest drive dates released • Y association to hear refugees • Senate decides on WSGA revisions • Frosh women\u27s representatives chosen; To be installed on Color Day, Thursday • St. John Terrell addresses Forum on drama history • Peirce - Pauli engagement • Dave Burger made king of annual Lorelei, Fri., Feb. 15 • Selective Service rules published by administration • Snyder receives Ph.D. degree Feb. 9 • S.R.C. discusses mental health • Two UC women attend confab on religious work • Chess Club plays F&M • Editorial: Word of welcome and some comments on evaluation • May Day • Brotherhood Week and the work of the National Conference of Christians and Jews • IRC to hear talk tonight on U.S. and Phillipines • Age of service • Cagers lose to Fords in overtime; Lose to Garnet five Saturday, 84-64 • Ursinus mermaids defeat Drexel Wed. • Belles register two net shutouts • William Yost resigns from court post • Padula stopped as matmen score win over E\u27town, Sat. • Chi Alpha hears Baker, sponsors weekly talks • Newman Club to hear discussion on J.H. Newman • Y heads discuss activities, plans at retreat, Sat. • Pre-med society hears Mercurio; Plans dinner • Fourteen go on mid-year trip to Washington, D.C. • Reed and Barton contest to run through Feb., Mar.https://digitalcommons.ursinus.edu/weekly/1421/thumbnail.jp
Bis(μ2-η2:η2-2,4,6-trimethylÂbenzonitrile)ÂbisÂ[(N-isopropyl-3,5-dimethylÂanilido)molybdenum(III)](Mo—Mo)
The title compound, [Mo2(C11H16N)4(C10H11N)2], is a dinuclear molybdenum complex with a formal metal–metal bond [Mo⋯Mo separation = 2.5946 (8) Å], four anilide-type ligands and two bridging mesityl nitrile groups. There are two inversion symmetric molÂecules in the unit cell (an inversion center is localized at the mid-point of the Mo—Mo bond), each with approximate non-crystallographic C
2h symmetry. The molÂecules contain disordered isopropyl and 3,5-C6H3Me2 groups on different anilido ligands; the major component having an occupancy of 0.683 (7). The complex was obtained in low yield as the product from the reaction between the bridging pyrazine adduct of molybdenum trisÂ-anilide ([μ2-(C4H4N2){Mo(C11H16N)3}2]) and mesityl nitrile with a loss of one anilido ligand
Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections
Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimicrobial options for vancomycin-resistant enterococci (VRE) are limited. Prior data suggests that daptomycin \u3e 6mg/kg/day may be used to treat enterococcal infections. We retrospectively evaluated the effectiveness and safety of high-dose daptomycin (HD-daptomycin) therapy (\u3e 6 mg/kg) in a multicenter cohort of adult patients with enterococcal infections to describe the characteristics and outcomes. Two-hundred and forty-five patients were evaluated. Enterococcus faecium was identified in 175 (71%), followed by 49 (20%) Enterococcus faecalis and 21 (9%) Enterococcus spp., overall 204 (83%) were VRE. Enterococcal infections included bacteremia (173, 71%), intra-abdominal (35, 14%) and bone/joint (25, 10%). The median dose and duration of HD-daptomycin was 8.2 mg/kg/day (IQR 7.7-9.7) and 10 days (IQR 6-15), respectively. Overall clinical success rate was 89% (193/218) and microbiological eradication was observed in 93% (177/191) of patients. The median time to clearance of blood cultures on HD-daptomycin was 3 days (IQR 2-5). Thirty-day all cause mortality rate was 27% and 5 (2%) patients developed daptomycin nonsusceptible enterococcal strains while on HD-daptomycin. Seven patients (3%) had creatine phosphokinase (CPK) elevation, yet no HD-daptomycin regimen was discontinued due to an elevated CPK and all patients were asymptomatic. Overall, there was a high frequency of clinical success and microbiological eradication in patients treated with HD-daptomycin for enterococcal infections, even in patients with complicated and difficult to treat infections. No adverse event-related discontinuation of HD-daptomycin was noted. HD-daptomycin may be an option for the treatment of enterococcal infections
Pulmonary delivery of vancomycin dry powder aerosol to intubated rabbits
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit. Recent studies showed that TGX-221 has anti-proliferative activity against PTEN-deficient tumor cell lines including prostate cancers. The objective of this study was to develop an encapsulation system for parenterally delivering TGX-221 to the target tissue through a prostate-specific membrane aptamer (PSMAa10) with little or no side effects. In this study, PEG-PCL micelles were formulated to encapsulate the drug, and a prodrug strategy was pursued to improve the stability of the carrier system. Fluorescence imaging studies demonstrated that the cellular uptake of both drug and nanoparticles were significantly improved by targeted micelles in a PSMA positive cell line. The area under the plasma concentration time curve of the micelle formulation in nude mice was 2.27-fold greater than the naked drug, and the drug clearance rate was 17.5-fold slower. These findings suggest a novel formulation approach for improving site-specific drug delivery of a molecular-targeted prostate cancer treatment
Recommended from our members
Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections
Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimicrobial options for vancomycin-
resistant enterococci (VRE) are limited. Prior data suggest that daptomycin at>6 mg/kg of body weight/day may be used
to treat enterococcal infections. We retrospectively evaluated the effectiveness and safety of high-dose daptomycin (HD-daptomycin)
therapy (>6 mg/kg) in a multicenter cohort of adult patients with enterococcal infections to describe the characteristics
and outcomes. Two hundred forty-five patients were evaluated. Enterococcus faecium was identified in 175 (71%), followed by
Enterococcus faecalis in 49 (20%) and Enterococcus spp. in 21 (9%); overall, 204 (83%) isolates were VRE. Enterococcal infections
included bacteremia (173, 71%) and intra-abdominal (35, 14%) and bone and joint (25, 10%) infections. The median dosage and
duration of HD-daptomycin were 8.2 mg/kg/day (interquartile range [IQR], 7.7 to 9.7) and 10 days (IQR, 6 to 15), respectively.
The overall clinical success rate was 89% (193/218), and microbiological eradication was observed in 93% (177/191) of patients.
The median time to clearance of blood cultures on HD-daptomycin was 3 days (IQR, 2 to 5). The 30-day all-cause mortality rate
was 27%, and 5 (2%) patients developed daptomycin-nonsusceptible enterococcal strains while on HD-daptomycin. Seven patients
(3%) had creatine phosphokinase (CPK) elevation, yet no HD-daptomycin regimen was discontinued due to an elevated
CPK and all patients were asymptomatic. Overall, there was a high frequency of clinical success and microbiological eradication
in patients treated with HD-daptomycin for enterococcal infections, even in patients with complicated and difficult-to-treat infections.
No adverse event-related discontinuation of HD-daptomycin was noted. HD-daptomycin may be an option for the
treatment of enterococcal infections.Keywords: Skin structure infections, Staphylococcus aureus, Outcomes registry, Vancomycin resistant enterococcus, Retrospective case series, Quinupristin dalfopristin, Cubicin(R), Complicated skin, Risk factors, Clinical outcomes, Bloodstream infection
Lessons from non-canonical splicing
Recent improvements in experimental and computational techniques that are used to study the transcriptome have enabled an unprecedented view of RNA processing, revealing many previously unknown non-canonical splicing events. This includes cryptic events located far from the currently annotated exons and unconventional splicing mechanisms that have important roles in regulating gene expression. These non-canonical splicing events are a major source of newly emerging transcripts during evolution, especially when they involve sequences derived from transposable elements. They are therefore under precise regulation and quality control, which minimizes their potential to disrupt gene expression. We explain how non-canonical splicing can lead to aberrant transcripts that cause many diseases, and also how it can be exploited for new therapeutic strategies
- …